Castle Biosciences Inc

NASDAQ:CSTLUnited States

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.

Contact Information

Headquarters

505 S Friendswood Drive, Suite 401FRIENDSWOOD, TX, United States 77546

Phone

281-796-9032

Fax

302-636-5454

Executives

Independent Chairman of the Board

Daniel Bradbury

President, Chief Executive Officer, Founder, Director

Derek Maetzold

Chief Financial Officer

Frank Stokes

Chief Operating Officer

Kristen Oelschlager

Chief Commercial Officer

Tobin Juvenal